Multicenter study of levodopa carbidopa intestinal gel in Parkinson's disease: the Turkish experience

Murat Gültekin1,*, Çağrı Ulukan2, Sabiha Tezcan2, Okan Doğu3, Hasnem Hanagası4, Başar Bilgici5, Ayşe Bora Tokcaer6, Raif Çakmur6, Bulent Elibol7, Meral Mirza1, Dilek İnce Günal8, Çiğdem Sevda Erer Özbek9, Gülay Kenangil10, Özge Yılmaz Küsbeci11, Muhittin Çenk Akbostancı2

1. Department of Neurology, Faculty of Medicine, Erciyes University, Kayseri, Turkey
2. Department of Neurology, Faculty of Medicine, Ankara University, Ankara, Turkey
3. Department of Neurology, Faculty of Medicine, Mersin University, Mersin, Turkey
4. Department of Neurology, Faculty of Medicine, Istanbul University, Istanbul, Turkey
5. Department of Neurology, Faculty of Medicine, Gazi University, Ankara, Turkey
6. Department of Neurology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey
7. Department of Neurology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
8. Department of Neurology, Faculty of Medicine, Marmara University, Istanbul, Turkey
9. Department of Neurology, Faculty of Medicine, Uludağ University, Bursa, Turkey
10. Department of Neurology, Medical Park Göztepe, Bahçeşehir University, Istanbul, Turkey
11. Department of Neurology, Bozyaka Training and Research Hospital, İzmir, Turkey

Background/aim: Our purpose was to determine the efficacy of levodopa carbidopa intestinal gel (LCIG) in a series of Turkish patients with Parkinson's disease (PD).

Materials and methods: We had telephone calls with 54 patients from 11 neurology centers who were on LCIG treatment, and 44 patients or their caregivers were included in an eight-item survey between September 2015 and June 2016. The reliability and validity of the survey were evaluated with intraclass correlation coefficients for every question separately.

Results: Average age of the patients were 63.48 and the duration of PD was 12.79 years. Average LCIG treatment period was 15.63 months. Percentages of the patients who reported they were 'better' after LCIG treatment were as follows: 80% for time spent off, 55% for dyskinesia, 65% for tremor, 85% for gait disorder, 50% for pain, 50% for sleep disorders, 42.5% for depression, 32.5% for incontinence, and 70% for activities of daily living. Cronbach's alpha was 0.795 and the intraclass correlation coefficient was reliable for the items.

Conclusion: As detected by a survey performed by telephone calls with good interrater reliability, patients with PD improve with LCIG treatment in many aspects of the disease.

Key words: Parkinson's disease, levodopa carbidopa intestinal gel, efficacy

1. Introduction

Parkinson's disease (PD) is the second most common progressive neurodegenerative disease occurring as a result of the dopaminergic neuron loss in the nigrostriatal pathway [1]. There can be motor as well as nonmotor symptoms in PD. As the disease progresses, the patients begin to need device-aided treatments such as apomorphine pump, deep brain stimulation (DBS), and levodopa/carbidopa intestinal gel (LCIG). Thanks to these treatments, both motor and nonmotor symptoms of the patients are significantly treated and activities of daily living (AoDL) become more comfortable [2].

Dopamine replacement with its oral precursor levodopa (L-DOPA) to stimulate striatal dopamine receptors is the gold-standard treatment of PD [3]. However, the therapeutic window of levodopa narrows progressively within years and most patients develop motor complications eventually, such as motor fluctuations and dyskinesia [4]. Due to its short plasma half-life, oral levodopa treatment cannot stimulate receptors in a continuous manner and causes oscillations of plasma levels, which are closely correlated with motor fluctuations [5]. In this period of PD, patients may need device-aided treatments. LCIG is a suspension administered to the
jejunal directly via percutaneous gastrojejunostomy tube to achieve more stabilized plasma levodopa levels. Based on multiple studies LCIG is effective in eliminating motor and nonmotor fluctuations and improving quality of life in advanced stages of PD [6–8].

In this study, we aimed to evaluate the efficacy of LCIG treatment for PD on motor and nonmotor symptoms and AoDL via a structured survey as a multicenter study.

2. Materials and methods
The Turkish Duodopa study was a cross-sectional, descriptive study designed to evaluate the efficacy of continuous LCIG infusion via a previously prepared survey to compare former and subsequent treatment of motor and nonmotor symptoms. This study was conducted between September 2015 and September 2016. Eleven neurology centers across Turkey were included in the study. The survey comprises a total of 9 questions. Four questions are related to motor symptoms (time spent off, dyskinesia, tremor, gait disorder), 4 questions are related to nonmotor symptoms (pain, sleep disorders, depression, incontinence), and one is related to AoDL. Questions in the survey are given in Appendix 1. Patients’ demographics, PD onset, and LCIG treatment duration were collected prospectively.

Fifty-four patients who were receiving LCIG were evaluated for this study. We could not enroll 10 patients because of missing contact information (n = 6), unwillingness to participate in the survey (n = 1), termination of therapy at the time of contact for loss of appetite (n = 2), and inadequate treatment response (n = 1). A total of 44 patients were evaluated. The patients and their caregivers were then asked to answer the survey on the telephone. Patients and their caregivers were asked to scale the effect of LCIG on every symptom, comparing the periods before and after the treatment as ‘better’, ‘same’, ‘worse’, ‘don’t know’, or ‘did not have this symptom’. Results were expressed as absolute numbers and frequencies. All interviews were recorded and two neurology residents listened to and evaluated these interviews separately. The protocol of the study was approved by the Ethics Committee of Ankara University.

2.1. Statistics
To compare the variables before and after LCIG initiation, the Wilcoxon matched pairs signed-rank test was used. The survey’s reliability and validity were assessed with Cronbach’s alpha and intraclass correlation coefficients (ICCs; interrater reliability) (Table 1). The statistical significance level was 0.05. SPSS 23.0 for Mac (IBM Corp., Armonk, NY, USA) was employed for data processing and analysis.

3. Results
We collected the patient data from 11 centers across Turkey specialized on movement disorders, and we tried to reach all the patients who were receiving LCIG treatment on the telephone. Twenty-two of 44 patients (50%) were female. The mean of the age of patients, duration of PD, and LCIG treatment duration were 63.48 ± 8.4 years, 12.79 ± 9.1 years, and 15.63 ± 9.46 months, respectively. The demographic data of patients are shown in Table 2.

The percentages of patients who reported ‘better’ motor symptoms for time spent off, dyskinesia, tremor, and gait disorder were 80%, 55%, 65%, and 85%, respectively. The percentages of nonmotor symptoms (pain, sleeping disorders, depression, and incontinence) that improved were 50%, 50%, 42.5%, and 32.5%, respectively. The details of the answers given by the patients are presented in the Figure.

According to the patients and their caregivers’ surveys on the telephone, 70% of all patients reported that they had improved in terms of AoDL after LCIG treatment. Motor symptoms responded significantly better than nonmotor symptoms. All of the parameters investigated except incontinence were rated as significantly better.

Cronbach’s alpha for the survey was 0.795. The reliability and validity were evaluated with the ICC for every question separately (Table 1) between raters.

Table 1. Intraclass correlation coefficient (ICC).

| Item                        | ICC  |
|-----------------------------|------|
| Motor Time spent ‘off’      | 0.981|
| Dyskinesia                  | 0.946|
| Tremor                      | 0.995|
| Gait disorder               | 0.792|
| Nonmotor pain               | 0.980|
| Sleep disorders             | 1.000|
| Depression                  | 0.958|
| Incontinence                | 0.991|
| Activities of daily living  | 0.995|

Table 2. Characteristics of the patients with Parkinson’s disease.

| Parameter                          | Value          |
|------------------------------------|----------------|
| N                                  | 44             |
| Age (years), mean (SD)             | 63.48 (8.4)    |
| Sex, n (%)                         | Male 22 (50)   |
| PD duration (years), mean (SD)      | 12.79 (9.1)    |
| LCIG duration (months), mean (SD)   | 15.63 (9.46)   |

PD: Parkinson’s disease, LCIG: Levodopa carbidopa intestinal gel.
The values for Cronbach’s alpha and ICCs gave rise to the thought that the telephone questionnaire can be used as a valid and reliable tool.

4. Discussion
In this study, we have conducted a quite simple survey to investigate the effect of LCIG on frequent motor and nonmotor symptoms of PD. The present study is the first study of LCIG treatment for PD patients in Turkey, with positive effects of the procedure on motor and nonmotor symptoms and AoDL.

Although there are numerous studies showing that LCIG is effective in treating PD [9–12], there is only one randomized, controlled, double-blind, double-dummy study to prove its efficacy [13]. Different types of scales (Unified PD Rating Scale: UPDRS, Parkinson Patient Quality of Life: PDQ, Nonmotor Symptoms Scale: NMSS, etc.) were employed in these studies to measure the efficacy of LCIG [14,15].

The improvement of motor symptoms was higher than nonmotor symptoms in our series. While the highest motor symptom recovery was for gait disorder (85%), highest nonmotor symptom recovery was for sleep (50%). The recovery of AoDL was found to be 50%. Some studies have also shown similar positive results [11,14]. It was demonstrated by Chang et al. that the decrease of ‘off’ time was 67% and 73% in comparison to baseline at the 6th and 12th months, respectively [6]. Fernandez et al. reported improvement of dyskinesia and at the same time increased ‘on’ time without troublesome dyskinesia at a rate of 62.9%, while the decrease of ‘on’ time with troublesome dyskinesia was 22.5% [7]. It was found by Buongiorno et al. that the efficacy of LCIG on gait disorders like falls and freezing of gait decreased the rate of such symptoms from 97% to 65% [8]. With regard to motor symptoms, the findings of the current study are compatible with the previous studies.

Băjenaru et al. evaluated 113 patients in their retrospective study conducted in nine centers located in Romania. With LCIG treatment, the ‘on’ period of the patients (period of improved mobility known as ‘on’ period) increased to 6.14 h on average, and dyskinesia periods decreased 29.4%. It was shown that the nonmotor symptoms and life quality scores of the patients improved dramatically [16]. In the study carried out by Cáceres-Redondo et al., 29 PD patients receiving LCIG treatment were monitored for two years. While similar improvements in motor and nonmotor symptoms of the patients were detected, it was revealed that although cognitive performance of the patients regressed, long-term well-being continued [17]. According to a large review
published recently, the evidence about the effect of LCIG on motor fluctuations and quality of life is of average quality, and the evidence about the effect of LCIG on nonmotor symptoms is of dramatically low quality (65%–14%) [18].

The effects of LCIG on motor and nonmotor symptoms of PD are shown in Table 3 [19–21].

There are a few limitations of our study, including a relatively small number of patients, retrieval of information through telephone calls, and a lack of information about side effects and complications.

In conclusion, we assume that the eight items of the survey developed to assess patient response to LCIG could be used as a telephone follow-up tool, especially with patients who have difficulty reaching a hospital.

**Conflict of interest**

All authors have declared no conflict of interest that may have influenced either the conduct or the presentation of the research.

**Informed consent**

All participants provided informed consent in the format required by the relevant authorities.

---

**Table 3. Efficacy of levodopa carbidopa intestinal gel on motor and nonmotor symptoms.**

| Authors                     | Year | ‘Off’ time | ‘On’ time with dyskinesia | UPDRS II | UPDRS III | NMSST, % improvement |
|-----------------------------|------|------------|--------------------------|----------|-----------|---------------------|
| Honig et al. [11]           | 2009 | -          | -                        | 11.6 ± 7.2 | 4.5 ± 2.2 | 56                  |
| Cáceres-Redondo et al. [17] | 2014 | 32.2 mo, 24.6 ± 7.2 | -                        | 16.5 ± 5.0 | 29.5 ± 6.4 | 17                  |
| Antonini et al. [19]        | 2015 | –4.7 ± 3.4 | –1.7 ± 5.0               | –3.1 ± 8.7 | –3.3 ± 11.0 | 29                  |
| Sensi et al. [20]           | 2014 | 24 mo, 1.0 ± 0.6 | -                        | -        | 24 mo, 34.7 ± 12.4 | 27                  |
| Bohlegra et al. [21]        | 2015 | 6 mo, 1.4   | -                        | -        | 19.6 ± 8.4 | 65                  |

NMSST: Nonmotor Symptom Scale Total score, mo: months, UPDRS: Unified Parkinson’s Disease Rating Scale

**References**

1. Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurology 2006; 5: 525-535.
2. Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet 2009; 373: 2055-2066.
3. Antonini A, Chaudhuri KR, Martinez-Martin P, Odin P. Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson’s disease. CNS Drugs 2010; 24: 119-129.
4. Tetrud JW. Balancing short-term symptom control and long-term functional outcomes in patients with Parkinson’s disease. CNS Spectrums 2007; 12: 275-286.
5. Stocchi F, Tagliati M, Olano CW. Treatment of levodopa-induced motor complications. Movement Disorders 2008; 23: 559-612.
6. Chang FCF, Kwan V, van der Poorten D, Mahant N, Wolfe N et al. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson’s disease. Journal of Clinical Neuroscience 2016; 25: 41-45.
7. Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VSC et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Movement Disorders 2015; 30: 500-509.
8. Buongiorno M, Antonelli F, Cámara A, Puente V, De Fabregues-Nebot O et al. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry. Parkinsonism & Related Disorders 2015; 21: 871-876.
9. Virhammar J, Nyholm D. Levodopa carbidopa enteral suspension in advanced Parkinson’s disease: clinical evidence experience. Therapeutic Advances in Neurological Disorders 2017; 10: 171-187.
10. Martinez-Martin P, Reddy P, Katzschlager R, Antonini A, Todorova A et al. EuroInf: A multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Movement Disorders 2015; 30: 510-516.
11. Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye G et al. Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Movement Disorders 2009; 24: 1468-1474.
12. Melgari J, Salomone G, Di Biase L, Marano M, Scrascia F et al. Dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion: management in clinical practice. Parkinsonism & Related Disorders 2005; 21: 327-328.
13. Slevin J, Fernandez HH, Zadikoff C, Hall C, Eaton S et al. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double blind pivotal study in advanced Parkinson’s disease patients. Journal of Parkinson’s Disease 2015; 5: 165-174.
14. Fernandez HH, Vanagunas A, Odin P, Espay AJ, Hauser RA et al. Levodopa carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results. Parkinsonism & Related Disorders 2013; 19: 339-345.

15. Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurology 2014; 13: 141-149.

16. Băjenaru O, Ene A, Popescu BO, Szasz JA, Sabau M et al. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience. Journal of Neural Transmission 2016; 123: 407-414.

17. Cáceres-Redondo MT, Carrillo F, Lama MJ, Huertas-Fernández I, Vargas-González L et al. Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease. Journal of Neurology 2014; 261: 561-569.

18. Wirdefeldt K, Odin P, Nyholm D. Levodopa carbidopa intestinal gel in patients with Parkinson's disease: a systematic review. CNS Drugs 2016; 30: 381-404.

19. Antonini A, Yegin A, Preda C, Bergmann L, Poewe W. Global long-term study on motor and nonmotor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients: 12-month interim outcomes. Parkinsonism & Related Disorders 2015; 21: 231-235.

20. Sensi M, Preda F, Trevisani L, Contini E, Gragnaniello D et al. Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients. Journal of Neural Transmission 2014; 121: 633-642.

21. Bohlega S, Abou Al-Shaar H, Alkhairallah T, Al-Ajlan F, Hasan N et al. Levodopa–carbidopa intestinal gel infusion therapy in advanced Parkinson’s disease: Single middle eastern center experience. European Neurology 2015; 74: 227-236.
### Appendix 1. Survey form used in the study.

| Evaluation of Motor and Nonmotor Symptoms | Better | Same | Worse | Unknown | She/he did not have that problem |
|------------------------------------------|--------|------|-------|---------|----------------------------------|
| **Motor symptoms**                       |        |      |       |         |                                  |
| Is there a change when she/he is unconscious (bad)? |        |      |       |         |                                  |
| Is there a change in her/his reflexes (saltatory, convolution, spasms - not shivering) during the day? |        |      |       |         |                                  |
| Is there a change in shivering?           |        |      |       |         |                                  |
| Is there a change her/his difficulty in walking and imbalance? |        |      |       |         |                                  |
| **Nonmotor symptoms**                    |        |      |       |         |                                  |
| Is there a change in aches?              |        |      |       |         |                                  |
| Is there a change in insomnia?           |        |      |       |         |                                  |
| Is there a change in senses of unhappiness, sadness, moodiness? |        |      |       |         |                                  |
| Is there a change in urinary incontinence problem? |        |      |       |         |                                  |
| **Daily life activities**                |        |      |       |         |                                  |
| Is there a change in her/his daily chores (eating, dressing, showering, etc.)? |        |      |       |         |                                  |
| **TOTAL**                                |        |      |       |         |                                  |
